Novel iPSC Derived Endothelial Cell Line for Translational Research
- Technology Benefits
- Decreased senescence with higher cell proliferation capacity Increased similarity to endothelial cells: EC-like morphology and expressed EC cellular markers
- Detailed Technology Description
- An improved endothelial cell (EC) line with improved proliferation capacity #therapeutics #stemcells #cardiology #researchtool #cellline
- *Abstract
-
Endothelial cells (ECs) that are differentiated from induced pluripotent stem cells (iPSCs) can be used in establishing disease models for personalized drug discovery and developing patient-specific, vascularized tissues or organs. However, a number of technical challenges are often associated with those cells in culture, including instability of the endothelial phenotype and limited cell proliferative capacity over time. Senescence is believed to be one of the key reasons for the limitations of working with iPSC derived cell lines. Northwestern researchers have created a transgenic iPSC-EC line that overcomes the effects of senescence using lentiviral vectors that overexpress Sirtuin1 (SIRT1), an enzyme known to prevent senescence by increasing nitric oxide production and proliferative capacity. These novel iPSC-ECs behave and appear more like endothelial cells with similar morphology and express higher percentage of EC markers. SIRT1 overexpressing iPSC-ECs continued to proliferate at passage 9 with high purity of ECs while iPSC-ECs without SIRT1 overexpression stopped proliferating after passage 5. This new cell line overcomes critical hurdles associated with the use of iPSC-ECs in translational research and its potential impact on personalized medicine.
- *Publications
- Jiang B, Jen M, Perrin L, Wertheim J, Ameer G (2015). SIRT1 overexpression maintains cell phenotype and function of endothelial cells derived from induced pluripotent stem cells. Stem Cells Development. 24(23): 2740-5.
- Country/Region
- USA
